Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Scott syndrome is an extremely rare congenital hemorrhagic disorder characterized by hemorrhagic episodes due to impaired platelet coagulant activity.
Features include: Abnormal bleeding tendency (abnormal bleeding) and Factor X activation deficiency.
Organ System | Phenotype Count |
|---|
Data assembled from 7 of 12 sources · Last updated Sep 17, 2026, 9:52 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Scott syndrome
Example Features
Blood and immune system | 1 | Abnormal bleeding tendency (abnormal bleeding) |
ANO6 encodes anoctamin 6 (910 aa). Small-conductance calcium-activated nonselective cation (SCAN) channel which acts as a regulator of phospholipid scrambling in platelets and osteoblasts. Highest expression in Artery Aorta (78.3 TPM) and Uterus (57.4 TPM).
Scott syndrome has been associated with mutations in the ANO6 gene on chromosome 12.
The ANO6 protein participates in ANO6 variant:Ca2+, ANO5:ANO5:Ca2+, ANO6:ANO6:Ca2+, and ANO6 exposes PS, PE on the platelet membrane pathways.
ANO6 is classified as a druggable target (Cell Surface, Ion Channel, and Transporter categories) with score 0.0.
Genetic testing for ANO6 is available. Testing is considered supportive for diagnosis.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Scott syndrome.
17 publications have been identified in PubMed for Scott syndrome. Research spans Case Report / Case Series (41%), Basic Science / Preclinical (29%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 41% |
Laboratory research | 5 | 29% |
Research summaries | 3 | 18% |
Disease patterns and progression | 1 | 6% |
New treatment approaches | 1 | 6% |
Ahmed A (2026). [PMID: 41742898](https://pubmed.ncbi.nlm.nih.gov/41742898/). *Haematologica*. [Gene Therapy / Novel Therapeutics]
Chattannavar G (2026). [PMID: 41486651](https://pubmed.ncbi.nlm.nih.gov/41486651/). *Ophthalmic Genet*. [Case Report / Case Series]
Jeanne M (2025). [PMID: 39798962](https://pubmed.ncbi.nlm.nih.gov/39798962/). *J Med Genet*. [Case Report / Case Series]
Kinney N (2025). [PMID: 40531908](https://pubmed.ncbi.nlm.nih.gov/40531908/). *PLoS One*. [Basic Science / Preclinical]
Al Dawood R (2025). [PMID: 40796410](https://pubmed.ncbi.nlm.nih.gov/40796410/). *Pathology*. [Review / Meta-Analysis]
Turgut GT (2025). [PMID: 40170577](https://pubmed.ncbi.nlm.nih.gov/40170577/). *Clin Genet*. [Epidemiology / Natural History]
Kageyama T (2025). [PMID: 40350307](https://pubmed.ncbi.nlm.nih.gov/40350307/). *Biol Pharm Bull*. [Basic Science / Preclinical]
Bonson G (2025). [PMID: 39874534](https://pubmed.ncbi.nlm.nih.gov/39874534/). *Shock*. [Basic Science / Preclinical]
Romanova RS (2025). [PMID: 40700061](https://pubmed.ncbi.nlm.nih.gov/40700061/). *Pediatr Rep*. [Case Report / Case Series]
Pulica R (2025). [PMID: 40069722](https://pubmed.ncbi.nlm.nih.gov/40069722/). *Cell Commun Signal*. [Review / Meta-Analysis]